Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata) on June 29, 2010, regarding events occurring on June 24, 2010, and June 28, 2010. The filing details the entry into a material definitive agreement for a private placement offering of securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $10.0 million.
- Net Proceeds: Approximately $9.2 million after deducting fees and expenses.
- Securities Issued: 3,571,436 units sold to institutional investors.
- Unit Composition: One share of common stock and one warrant to purchase 0.75 of a share.
- Offering Price: $2.80 per unit.
- Warrant Terms: Exercise price of $3.25 per share; exercisable immediately for three years.
- Placement Agent Fees: $700,001 cash fee (7% of gross proceeds) plus a warrant to purchase 250,001 shares.
- Expenses: $25,000 reimbursed to the placement agent.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of 3,571,436 new shares of common stock and warrants covering an aggregate of 2,678,577 shares, plus the placement agent warrant for 250,001 shares. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as this is a transaction-specific report.
Outlook, Risks, and Contingencies
The offering was anticipated to close on June 29, 2010, subject to customary closing conditions. The warrants issued contain adjustment provisions for stock splits, dividends, rights offerings, pro-rata distributions, and fundamental transactions. However, the filing explicitly states that the warrants do not contain "price protection provisions" regarding subsequent securities issuances. The securities were registered under a Form S-3 filed in 2008.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds received by the company.
- Confirm the total number of shares outstanding post-offering to assess dilution impact.
- Review the full text of the Placement Agent Agreement and Warrants (Exhibits 1.01, 1.02, and 4.01) for specific anti-dilution or redemption clauses.
- Check subsequent filings for the use of the $9.2 million in net proceeds.
- Note the discrepancy between the metadata company name (Palisade Bio) and the filing registrant (Neuralstem, Inc.).